The global erectile dysfunction drugs market size was estimated to be at USD 2.49 billion in 2017. The erectile dysfunction or impotence is characterized by inability to sustain or build up a penile erection during sexual intercourse. According to World Health Organization statement, for the emotional, physical and wellbeing of the individual, and to the economic and social development of countries and communities, sexual health is a fundamental thing. The common causes of erectile dysfunction engage side effects of medicines, neurogenic disorders, aging, multiple sclerosis, psychological causes, and diabetes, and lifestyle changes.
The increasing elderly population and high rate of chronic diseases such as kidney failure, diabetes, hypertension, hormonal imbalance, and neurological disorders are increasing demand for erectile dysfunction drugs globally. Moreover, rising awareness among patients about erectile dysfunction and availability of treatment are contributing significantly towards the growth of erectile dysfunction drugs market globally. But, even with of rising demand for erectile dysfunction drugs, the global market is facing decline owing to patent expiry of market blockbuster drugs such as Viagra etc. On the contrary, the patent expiration of major brands is generating major opportunity for generic manufacturers to enter in the erectile dysfunction drugs market. Moreover, players in various stages of pipeline are also expected to generate huge opportunity for global erectile dysfunction drugs market globally.
By Component Type
By Dosage Form
By Distribution Channel
Know more about this report: request for sample pages
The global market for erectile dysfunction drugs is segmented by the product, component type, dosage form, end user, and geographically. On the basis of product, the global erectile dysfunction market is segmented into Viagra (Sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream), and Others. By component type, the global erectile dysfunction market is further segmented into Testosterone, Phosphodiestarse - 5 Inhibitors (PDE5I), Alprostadil, and others. The Phosphodiestarse - 5 Inhibitors drugs are widely prescribed drugs to treat erectile dysfunction and hence accounted major share in global erectile dysfunction drugs market. Sildenafil, Vardenafil, Tadalafil, Avanafil, Udenafil are the mostly used drugs of Phosphodiestarse - 5 Inhibitors. Oral PDE inhibitors are an efficacious, convenient, and widely available treatment choice for erectile dysfunction. These drugs inhibit type 5 PDE inside the cavernosal smooth muscle and avoid the breakdown of cGMP to GMP. The nitric oxide mediated smooth muscle relaxation is therefore facilitated in both the cavernosal arteries and corpus cavernosum. sildenafil, tadalafil, and vardenafil are the three main PDE-5 inhibitors effective in a wide range of patient groups.
By dosage form, the global erectile dysfunction market is further sub segmented into topical, oral, injections, and others. The oral segment accounted major share in global erectile dysfunction drugs market. The injections are injected in penis. The injection causes the muscle relaxation of penis and encourages blood to flow into penis. The topical drugs are applied over the body.
On the basis of distribution channel, the global erectile dysfunction drugs market is further segmented into, hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. By distribution channel, retail pharmacies accounted major share in global erectile dysfunction drugs market. The easy availability of drugs and large number of retail pharmacies are the factors contributed towards the large share of segment in the global market. The online pharmacies segment is expected to register high growth over the forecast period. The rising online pharmacies globally are expected to drive the growth of segment in global erectile dysfunction drugs market globally
By geography, the global erectile dysfunction drugs market is segmented into five major regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America counted major share in global erectile dysfunction drugs market. The high awareness among the people about the erectile dysfunction, prolongation of patent exclusivity rights for Viagra in U.S. and presence of large number of players in the region are the key factors contributed towards high market share in the global erectile dysfunction drugs market. The Asia Pacific is expected to grow at high rate in the coming years owing to accelerated economical growth; increasing aging population, and increasing awareness, is expected to propel the growth of region over the forecast period.
The key players in the erectile dysfunction drugs market include Bayer AG, Pfizer, Eli Lilly & Co., Vivus, Inc., S.K. Chemicals Co. Ltd., Dong-A Pharmaceutical Co. Ltd, Meda Pharmaceuticals, Apricus Biosciences, Vivus, Inc. among others.